C'mon Mozz "reasonably received back then", seriously? We are...

C'mon Mozz "reasonably received back then", seriously? We are living in the now and the hard truths are that none of the 32+ NDA signees (professionals from Pharma companies that do this for a living) recognised anything in the data room, that would have them want to stump up anything, or recommend to their boards that they should part with a small percentage of their R&D budgets.
In fact, here's what the top 20 R&D spends looked like back in 2022 and none of them decided PAR was worth any of their time or money.

Ranked by sales revenue

1			Nett Income 2022	R&D expense 2022	0m as % of R&D
2	#1-Pfizer	$31bn	$12.3bn	0.84%
3	J&J	$21.2bn	$14.6bn	0.68%
4	Roche	$13bn	$15bn	0.66%
5	Merck	$14.5bn	$11.8bn	0.85%
6	Abbvie	$11.7bn	$6.5bn	1.54%
7	Novartis	$6.9bn	$9bn	1.11%
8	Bristol Myers	$6.3bn	$9.4bn	1.06%
9	Sanofi	$8.8bn	$6.7bn	1.5%
10	AstraZenaca	$3.2bn	$9.6bn	1.04%
11	Glaxo	$18bn	$6bn	1.69%
12	#20- BionTech	$9bn	$2bn	5%
13